Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Heck

Internal Medicine Kinston, NC Doctor of Osteopathy

NPI 1780670695 CMS profile 80928

744 Airport Rd, Kinston, NC 28504

Open in the dashboard

General payments

$10,399

688 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Heck of Kinston, NC is reported in the CMS Open Payments database as having received $10,399 across 688 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40 2
2024 General $1,023 61
2023 General $1,908 128
2022 General $1,867 114
2021 General $1,557 115
2020 General $1,707 123
2019 General $2,297 145

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Heck
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gary Heck were reported at $40. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gary Heck Internal Medicine median Middle half National median
2019 $2,297 $159 $48–$570 $163
2020 $1,707 $119 $33–$402 $114
2021 $1,557 $135 $37–$521 $132
2022 $1,867 $141 $42–$496 $149
2023 $1,908 $149 $45–$519 $160
2024 $1,023 $154 $47–$537 $164
2025 $40 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,509 119 payments
  2. Amgen Inc. $1,281 78 payments
  3. Lilly USA, LLC $774 51 payments
  4. AbbVie, Inc. $769 53 payments
  5. AstraZeneca Pharmaceuticals LP $605 29 payments
  6. GlaxoSmithKline, LLC. $541 40 payments
  7. Pfizer Inc. $465 34 payments
  8. Sanofi-Aventis U.S. LLC $444 30 payments
  9. Abbott Laboratories $421 26 payments
  10. Amarin Pharma Inc. $418 30 payments
  11. Other $3,172 198 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,293 682 payments
  2. Education $105 6 payments
Products named General payments · program years 2019–2025
  1. Ozempic $852 71 payments
  2. Repatha $791 54 payments
  3. RYBELSUS $680 57 payments
  4. Otezla $559 32 payments
  5. TRELEGY ELLIPTA $461 34 payments
  6. JARDIANCE $413 25 payments
  7. VRAYLAR $376 23 payments
  8. Vascepa $372 27 payments
  9. Prolia $371 21 payments
  10. FreeStyle Libre 2 $363 23 payments
  11. Other $9,049 602 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 134 drugs

Part D claims

7,335

Median for Internal Medicine: 777

Drug cost

$476,190

Median for Internal Medicine: $73,373

Branded share of claims

19.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 78 $61,175
Jardiance Empagliflozin Brand 58 $49,926
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 64 $47,826
Ozempic Semaglutide Brand 25 $31,268
Januvia Sitagliptin Phosphate Brand 35 $28,983
Repatha Sureclick Evolocumab Brand 46 $25,303
Mounjaro Tirzepatide Brand 18 $20,372
Tresiba Flextouch U-200 Insulin Degludec Brand 27 $19,188
Linzess Linaclotide Brand 32 $16,956
Xarelto Rivaroxaban Brand 23 $15,718

The 10 drugs with the highest cost, of 134 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 128 billing codes

Paid by Medicare

$172,295

Of which drugs: $37,516

Medicare patients

424

Average age 77

Services billed

7,674

239 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 42%
Diabetes 36%
Chronic kidney disease 35%
Heart failure 30%
Atrial fibrillation 25%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 15 1,080 $22,314
Vaccine for influenza for injection into muscle 90662 Office 45 45 $3,642
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 32 194 $139

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $100
$100 64 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $66
$66 14 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $57
$57 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $52
$52 — —
MOUNJARO
  • Lilly USA, LLC $49
$49 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

688 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record